Skip to content

Multimodal Program for Cancer Related Cachexia Prevention

Effectiveness of a Multimodal Education and Support Program for the Prevention of Cancer Related Cachexia for Patients and Their Family Caregiver

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04627376
Enrollment
60
Registered
2020-11-13
Start date
2020-09-24
Completion date
2026-06-30
Last updated
2022-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia, Cancer, Educational Problems, Malnutrition, Neoplasms

Keywords

cachexia, prevention, management, malnutrition

Brief summary

The aim of the study is to evaluate the effectiveness of a multifactorial education and support program for the prevention of cancer-related cachexia syndrome, for patients and their family caregivers during anti-cancer treatment.

Detailed description

After being informed about the study and the need to nominate a family caregiver, all patients and their family caregiver giving written informed consent, they will undergo a 12-weeks multimodal program. Randomly they will divided into two groups (intervention and control). This 12-weeks multimodal program includes 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management.

Interventions

OTHERMultimodal education and support program for cancer related cachexia prevention

12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.

Sponsors

German Oncology Center, Cyprus
CollaboratorOTHER
Cyprus University of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years old or older 2. Participants must be diagnosed with solid tumour (stomach, colorectal, pancreas, breast, lung) 3. Participants needing chemotherapy/immunotherapy/hormone therapy/target therapy 4. Participants must be normal or pre cachectic as defined by the guidelines 5. Read and understand Greek or English

Exclusion criteria

1. Haematologic tumors 2. Parenteral Nutrition 3. ECOG Performance status \>2 or Karnofsky Performance Status \<60% 4. Participant who can not introduce a family caregiver 5. Participants in cachexia or refractory cachexia stage as defined by the guidelines below: * \>5% weight loss over the past 6 months (in absence of simple starvation); OR * BMI \<20 and any degree of weight loss \>2%; OR * Appendicular skeletal muscle index consistent with sarcopenia (whole body fat-free mass index without bone determined by bioelectrical impedance (men \<14.6 kg/m²; women \<11.4 kg/m²) and weight loss \>2% 6. Patients who use complementary therapies (ex-acupuncture)

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in pre-cachexia stage against cachexia criteria at 12 weeksBaseline and week 4, week 8, week 12To assess the patient's baseline cancer cachexia stage with weight (weight loss \<5% in previous three months, kg), height (cm) and BMI (BMI \> 20) measurements.

Secondary

MeasureTime frameDescription
Change from baseline in inflammation based on the CRP test at 12 weeksBaseline and week 4, week 8, week 12Blood test for C-reactive protein (mg/L). CRP level greater than 10 mg/L is a sign of active inflammation.
Change from baseline in edema according to albumin levels from baseline at 12 weeksBaseline and week 4, week 8, week 12Blood test for Albumin Levels. normal ranges \>35g/L
Change from baseline of patient's Quality of life on the FAACT questionnaire (score) at 12 weeksBaseline and week 12Participants will fill the questionnaire at baseline and at week 12 to compare the score of FAACT. The FAACT questionnaire is validated, self-reported instrument (28-item) assessing the quality of life of cancer patients with any tumour type. Possible scores range from 0 (lower quality of life) to 112 (better quality of life). Change = Week 12 - Baseline
Change from baseline (week 4) of family caregiver's Quality of life on the CarGOQoL questionnaire (score) at 12 weeksWeek 4 and week 12Participants will fill the questionnaire at week 4 and at week 12 to compare the score of CarGOQoL. The CarGOQoL questionnaire is validated, self-reported instrument (29 items investigating 10 domains) assessing the quality of life of family caregivers. Possible scores range from 0 (lower quality of life) to 100 (better quality of life). Change = Week 12 - Week 4

Countries

Cyprus

Contacts

Primary ContactAndreas Charalambous, PhD
andreas.charalambous@cut.ac.cy00357-25002011
Backup ContactConstantina Cloconi, MSc
tina_cl92@hotmail.com00357-96718110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026